Sungmin Jung

Sungmin Jung

Auto-generated profile, based on publicly available information

Sungmin Jung

Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2022 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
MJMin Kyung Jung
Min Kyung Jung
SJSeong Dong Jeong
Seong Dong Jeong
JNJi Yun Noh
Ji Yun Noh
DKDong-Uk Kim
Dong-Uk Kim
SJSungmin Jung
Sungmin Jung
ESEui-Cheol Shin
Eui-Cheol Shin

19 January 2024 in Science Immunology
Verified
Journal Article
Closed access
SKSang-Hoon Kim
Sang-Hoon Kim
JKJihye Kim
Jihye Kim
SJSungmin Jung
Sungmin Jung
JNJi Yun Noh
Ji Yun Noh
JKJinnam Kim
Jinnam Kim
ESEui-Cheol Shin
Eui-Cheol Shin
Here, we examine peripheral blood memory T cell responses against the SARS-CoV-2 BA.4/BA.5 variant spike among vaccinated individuals with or without Omicron breakthrough infections. We provide evidence supporting a lack of original antigenic sin in CD8 + T cell responses targeting the spike. We show that BNT162b2-induced memory T cells respond to the BA.4/BA.5 spike. Among individuals with BA.1/BA.2 breakthrough infections, IFN-γ–producing CD8 + T cell responses against the BA.4/BA.5 spike increased. In a subgroup with BA.2 breakthrough infections, IFN-γ–producing CD8 + T cell responses against the BA.2-mutated spike region increased and correlated directly with responses against the BA.4/BA.5 spike, indicating that BA.2 spike–specific CD8 + T cells elicited by BA.2 breakthrough infection cross-react with the BA.4/BA.5 spike. We identified CD8 + T cell epitope peptides that are present in the spike of BA.2 and BA.4/BA.5 but not the original spike. These peptides are fully conserved in the spike of now-dominant XBB lineages. Our study shows that breakthrough infection by early Omicron subvariants elicits CD8 + T cell responses that recognize epitopes within the spike of newly emerging subvariants.

20 August 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
SJSeung Hyuck Jeon
Seung Hyuck Jeon
KSKoung Jin Suh
Koung Jin Suh
SJSungmin Jung
Sungmin Jung
MJMinwoo Jeon
Minwoo Jeon
HJHo Cheol Jang
Ho Cheol Jang
ESEui-Cheol Shin
Eui-Cheol Shin
Purpose: PD-1/PD-L1 blockade modulates the responses of T cells, including regulatory T cells (Treg). Understanding the changes of Treg upon PD-1/PD-L1 blockade in patients with cancer and their association with therapeutic response will provide clues about the mechanisms underlying resistance to treatment. Experimental Design: Peripheral blood samples were acquired before and at 1 week following treatment from 65 patients [triple-negative (TN), n = 35; luminal, n = 30] enrolled in the KORNELIA phase II trial, which evaluated the efficacy of chemoimmunotherapy combining nivolumab and eribulin in patients with HER2-negative breast cancer. The immunophenotype of circulating immune cells was analyzed by flow cytometry. T-cell receptor sequencing was used to track the clonotypes of circulating Treg in relation to the tumor-related clonotypes. Results: In both breast cancer subtypes, chemoimmunotherapy increased the proportion of circulating Treg as well as their proliferative response. Notably, we observed an increased frequency of the circulating Treg population with tumor-related clonotypes after treatment in triple-negative breast cancer (TNBC). Moreover, increased proliferation of circulating Treg was associated with poor response to treatment, only in TNBC. This association between circulating Treg proliferation and poor clinical response was further supported by the analysis of publicly available single-cell transcriptomic data from patients with TNBC. A Treg-based biomarker predicted both clinical response and survival outcomes in TNBC. Conclusions: Our results indicate that the proliferation and expansion of tumor-related clonotypes among circulating Treg are related to chemoimmunotherapy resistance, particularly in TNBC.


3 November 2025
Verified
Other
Open access
SJSeung Hyuck Jeon
Seung Hyuck Jeon
KSKoung Jin Suh
Koung Jin Suh
SJSungmin Jung
Sungmin Jung
MJMinwoo Jeon
Minwoo Jeon
HJHo Cheol Jang
Ho Cheol Jang
ESEui-Cheol Shin
Eui-Cheol Shin
Table S3 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer

3 November 2025
Verified
Other
Open access
SJSeung Hyuck Jeon
Seung Hyuck Jeon
KSKoung Jin Suh
Koung Jin Suh
SJSungmin Jung
Sungmin Jung
MJMinwoo Jeon
Minwoo Jeon
HJHo Cheol Jang
Ho Cheol Jang
ESEui-Cheol Shin
Eui-Cheol Shin
Table S2 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer